Pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as preparation method and application of glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel

By combining glycyrrhizic acid with polymyxin B and cross-linking with calcium chloride to form a self-assembled hydrogel, the problems of insufficient drug loading capacity of the nanocarrier system and poor solubility of glycyrrhizic acid were solved, achieving efficient bacterial inhibition and wound healing effects and reducing the risk of antibiotic resistance.

CN120643667APending Publication Date: 2025-09-16ANHUI AGRICULTURAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202510730349.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-03
Publication Date
2025-09-16

AI Technical Summary

Technical Problem

The drug loading capacity of existing nanocarrier systems is limited, resulting in the use of high-concentration carriers increasing the risk of adverse reactions and systemic toxicity. The poor solubility of glycyrrhizic acid in water limits its application in the biomedical field.

Method used

By combining glycyrrhizic acid with polymyxin B, a self-assembled carrier-free hydrogel was formed by cross-linking glycyrrhizic acid with calcium chloride, which improved the mechanical strength and achieved 100% drug loading rate.

Benefits of technology

Significantly enhance the inhibitory and killing effects on methicillin-resistant Staphylococcus aureus, reduce the use of polymyxin B, alleviate antibiotic resistance, improve drug utilization and enhance biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120643667A_ABST
    Figure CN120643667A_ABST
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises glycyrrhizic acid and polymyxin B. According to the pharmaceutical composition, the inhibition effect on MRSA is enhanced through drug combination, the use of polymyxin B is reduced through the synergistic effect, and the development pressure of antibiotic drug resistance is relieved. According to the hydrogel formed by crosslinking the glycyrrhizic acid and the calcium chloride, the glycyrrhizic acid and the calcium chloride are crosslinked to form the hydrogel, and the calcium chloride is introduced into a glycyrrhizic acid system to increase the mechanical strength of the glycyrrhizic acid hydrogel, so that the glycyrrhizic acid hydrogel can be better attached to a wound. The invention provides a glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel and a preparation method of the glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel. The hydrogel does not contain any inert carrier component at all, the drug loading rate of 100% is achieved, and adverse reactions possibly caused by a traditional carrier system are effectively avoided.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A pharmaceutical composition, characterized in that include: Glycyrrhizic acid and polymyxin B; the molar ratio of glycyrrhizic acid to polymyxin B is (14-60):

1.

2. The pharmaceutical composition according to claim 1, characterized in that The mass concentration of polymyxin B in the pharmaceutical composition is 0.008-1.024 mg / mL, and the mass concentration of glycyrrhizic acid is 0.156-25 mg / mL.

3. The pharmaceutical composition according to claim 1, characterized in that The glycyrrhizic acid includes a glycyrrhizic acid monomer solution and / or a hydrogel synthesized by glycyrrhizic acid and calcium chloride; the hydrogel synthesized by glycyrrhizic acid and calcium chloride is synthesized by cross-linking glycyrrhizic acid and calcium chloride; the molar ratio of glycyrrhizic acid to calcium chloride is 1:(10-40).

4. The pharmaceutical composition according to claim 3, characterized in that The preparation method of the hydrogel synthesized by glycyrrhizic acid and calcium chloride comprises: The glycyrrhizic acid solution is mixed with calcium chloride; the mixed solution is cross-linked to obtain a hydrogel synthesized from the glycyrrhizic acid and calcium chloride.

5. A carrier-free hydrogel, characterized in that include: Glycyrrhizic acid, polymyxin B and calcium chloride; the molar ratio of glycyrrhizic acid to polymyxin B is (14-60):1; the molar ratio of glycyrrhizic acid to calcium chloride is 1:(10-40).

6. The carrier-free hydrogel according to claim 5, characterized in that The mass concentration of glycyrrhizic acid in the hydrogel is 0.156-25 mg / mL, the mass concentration of polymyxin B is 0.008-1.024 mg / mL, and the mass concentration of calcium chloride is 0.05-1 g / mL.

7. A method for preparing the carrier-free hydrogel according to claim 5 or 6, characterized in that: include: After mixing glycyrrhizic acid solution, calcium chloride and polymyxin B, the mixed solution is cross-linked to obtain a carrier-free hydrogel.

8. The preparation method according to claim 7, characterized in that: The cross-linking temperature is 20-23° C.; the cross-linking time is 8-24 hours.

9. Use of the pharmaceutical composition according to any one of claims 1 to 4, the carrier-free hydrogel according to claim 5 or 6, or the carrier-free hydrogel prepared by the preparation method according to claim 7 or 8 in the preparation of antibacterial products and / or food preservation; the bacteria include Staphylococcus aureus and / or Escherichia coli.

10. Use of the pharmaceutical composition according to any one of claims 1 to 4, the carrier-free hydrogel according to claim 5 or 6, or the carrier-free hydrogel prepared by the preparation method according to claim 7 or 8 in the preparation of a drug for promoting wound healing.

Citation Information

Cited By

  • Middle-internal phase Pickering emulsion gel as well as preparation method and application thereof

    CN121081676A